The string of megadeals announced in the first half of 2024 reflect a growing confidence among US dealmakers. But can the bull run be sustained?
Megadeals were firmly on the agenda in H1 as more stable inflation and...more
9/30/2024
/ Acquisitions ,
Buyers ,
Capital Markets ,
Domestic Dealmaking ,
Global Dealmaking ,
Investment ,
Investors ,
Lenders ,
Mergers ,
Regulatory Agenda ,
Sellers
Although the record-breaking deal activity of 2021 spilled over into 2022, headwinds in the first quarter developed into a significant slowdown during the rest of 2022, with an expectation of continued slowness as we enter...more
1/30/2023
/ Acquisitions ,
Buyers ,
Capital Markets ,
CFIUS ,
Coronavirus/COVID-19 ,
Cryptocurrency ,
Department of Justice (DOJ) ,
Domestic Dealmaking ,
Environmental Social & Governance (ESG) ,
EU ,
Federal Trade Commission (FTC) ,
Financial Institutions ,
Financial Services Industry ,
Global Dealmaking ,
Investment ,
Investors ,
Mergers ,
Pharmaceutical Industry ,
Private Equity ,
Publicly-Traded Companies ,
Real Estate Market ,
Securities and Exchange Commission (SEC) ,
Sellers ,
Special Purpose Acquisition Companies (SPACs) ,
Technology
M&A started strong in 2022 with robust deal activity and megadeals dominating the landscape that was largely the result of unprecedented spillover from 2021. But then, things took a turn and deals stalled in the second half...more
As predicted in our previous M&A report, 2022 has not lived up to the runaway performance of 2021. As activity—still at impressive levels considering everything that has been thrown at the deal market—takes a breather, we...more
9/13/2022
/ Acquisitions ,
Buyers ,
Capital Markets ,
Domestic Dealmaking ,
EBITDA ,
Global Dealmaking ,
High Yield Bonds ,
Interest Rates ,
Leveraged Loans ,
Mergers ,
Private Equity
Explore the data The headline for the first half of 2022 is that US M&A markets are still remarkably healthy, despite a confluence of headwinds. Without question, 2021 was an exceptional year, fueled by pent-up demand,...more
8/23/2022
/ Acquisitions ,
Capital Markets ,
Deal Price ,
Domestic Dealmaking ,
EBITDA ,
Environmental Social & Governance (ESG) ,
Fair Market Value ,
Global Dealmaking ,
Greenwashing ,
Market Price ,
Mergers ,
Popular ,
Private Equity ,
Publicly-Traded Companies ,
Special Purpose Acquisition Companies (SPACs)
Dealmakers in almost every industry had an outstandingly busy 2021. With just a few exceptions, the M&A boom swept across the US economy with deal values, in particular, up significantly on 2020 totals.
Nevertheless,...more
2/18/2022
/ Acquisitions ,
Biotechnology ,
Capital Markets ,
Domestic Dealmaking ,
Energy Sector ,
Financial Services Industry ,
Healthcare ,
Investment ,
Investors ,
Mergers ,
Pharmaceutical Industry ,
Retail Market ,
Technology Sector
M&A markets appeared to defy gravity through 2021. Globally, dealmakers were highly active, with values exceeding US$5 trillion for the first time ever. Total deal value rose by 81 percent on 2020 totals to US$5.75 trillion,...more
Five factors that will shape dealmaking over the coming 12 months -
Last year will be a very tough act to follow. M&A values and volumes soared on the back of confident public markets, strong deal financing options and a...more
2/7/2022
/ Acquisitions ,
Coronavirus/COVID-19 ,
Domestic Dealmaking ,
Federal Trade Commission (FTC) ,
Interest Rates ,
Mergers ,
Private Equity ,
Regulatory Oversight ,
Securities and Exchange Commission (SEC) ,
Special Purpose Acquisition Companies (SPACs) ,
Stock Markets
Heightened interest in medical suppliers, contract research organizations and biotech firms resulted in an impressive year for healthcare dealmaking-
Dealmaking within the pharma, medical and biotech sector continued from...more
12/21/2021
/ Acquisitions ,
Biotechnology ,
Coronavirus/COVID-19 ,
Domestic Dealmaking ,
Healthcare ,
Investment ,
Investors ,
Life Sciences ,
Medical Research ,
Mergers ,
Special Purpose Acquisition Companies (SPACs) ,
Technology
After a turbulent 18 months which saw M&A crash before an impressive return to form, H2 2021 is set for continued strong deal activity, as well as new challenges -
US M&A progressed steadily through the first half of 2021....more
8/10/2021
/ Acquisitions ,
Biden Administration ,
CFIUS ,
Coronavirus/COVID-19 ,
Domestic Dealmaking ,
Enforcement ,
Global Dealmaking ,
Investment ,
Liquidity ,
Mergers ,
National Security ,
Securities and Exchange Commission (SEC) ,
Special Purpose Acquisition Companies (SPACs) ,
Stock Markets ,
Technology Sector ,
Vaccinations